. Author manuscript; available in PMC: 2013 Oct 15.

Published in final edited form as: Clin Cancer Res. 2012 Aug 15;18(20):5773–5779. doi: 10.1158/1078-0432.CCR-12-1153

Table 2.

Patient characteristics by Progression-Free Survival (PFS) and Overall Survival (OS)

		n	2-year PFS (%) (95% CI)	p-value	2-year OS (%) (95% CI)	p -value
	Overall	54	9 (1,17)		19 (7,31)
Age	Age 17 years or younger	29	14 (2,26)	0.1	30 (12,48)	0.07
Age	Age 18 years or older	25	4 (0,12)	0.1	5 (0,15)	0.07
Gender	Female	26	4 (0,12)	0.1	9 (0,21)	0.1
Gender	Male	28	14 (0,28)	0.1	29 (9,49)	0.1
Tumor Location	Thoracic	31	3 (0,9)	0.04	15 (1,29)	0.1
	Head/Neck	19	16 (0,32)		27 (2,52)
	Other Locations	4	25 (0,68)		25 (0,68)
Tumor Histology	Carcinoma with Squamous Differentiation	21	14 (0,30)	0.4	33 (9,57)	0.2
	Carcinoma without Squamous Differentiation	23	4 (0,12)		6 (0,18)
	Other Histology	9	11 (0,33)		22 (0,49)
NUT Translocation	BRD4-NUT	38	8 (0,12)	0.1	12 (0,24)	0.4
	BRD3-NUT	3	0		33 (0,86)
	NUT-Variant	12	17 (0,39)		33 (6,60)
Metastases	No Metastases	21	19 (1,37)	0.04	25 (3,37)	0.1
Metastases	Metastases	32	3 (0,9)	0.04	16 (2,26)	0.1
Lymph Node Involvement	No Involvement	29	10 (0,22)	0.3	20 (2,38)	0.3
Lymph Node Involvement	Involvement	25	8 (0,18)	0.3	18 (2,34)	0.3
Extent of Surgical Resection	Less than Gross Total	10	10 (0,30)	0.01	44 (7,81)	0.03
	Complete	5	60 (17,100)	0.01	80 (45,100)	0.03
	Less than Gross Total or No Surgical Resection	49	4 (0,10)	0.001	12 (0,24)	0.002
	Complete	5	60 (17,100)	0.001	80 (45,100)	0.002
Initial Radiotherapy	No	27	0	<0.0001	5 (0,15)	0.0003
Initial Radiotherapy	Yes	26	19 (3,35)	<0.0001	35 (13,57)	0.0003
Chemotherapy Regimen	Platinum-based	33	9 (0,19)	0.6	22 (4,40)	0.3
	Other	20	10 (0,24)	0.6	15 (0,31)	0.3
	Anthracycline/Alkylator-based	17	18 (0,36)	0.6	28 (4,40)	0.4
	Other	36	6 (0,14)	0.6	15 (1,29)	0.4

Abbreviation: CI (confidence interval)